Patents by Inventor Andy Minn

Andy Minn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of predicting and reducing risk of metastasis of breast cancer to lung
    Patent number: 8178505
    Abstract: A signature for breast cancer tissue derived from a patient is established that is indicative of the virulence and risk of lung metastasis by determining the expression levels to define a sample signature, and comparing this sample signature to a reference signature. The reference signature defines a standard expression level for each gene and a significant change direction, i.e., either overexpressed or underexpressed. A sample signature that differs from the reference signature in the significant change direction for a predetermined number of the genes tested is indicative of a significant risk of lung metastasis. This determination is used to define appropriate treatment and monitoring options for the patient.
    Type: Grant
    Filed: January 5, 2006
    Date of Patent: May 15, 2012
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Joan Massague, Gaorav P. Gupta, Andy Minn
  • Prognosis and Therapy Predictive Markers and Methods of Use
    Publication number: 20110200998
    Abstract: Disclosed is a set of genes differentially expressed in chemotherapy and radiation resistant tumors useful in predicting response to therapy and assessing risk of local-regional failure, survival and metastasis in cancer patients. Also disclosed are methods for characterizing tumors according to gene expression and kits for use in the methods of the invention.
    Type: Application
    Filed: February 8, 2011
    Publication date: August 18, 2011
    Applicant: THE UNIVERSITY OF CHICAGO
    Inventors: Ralph Weichselbaum, Bernard Roizman, Andy Minn, Nikolai Khodarev, Edwardine Labay
  • Prognosis and therapy predictive markers and methods of use
    Patent number: 7892740
    Abstract: Disclosed is a set of genes differentially expressed in chemotherapy and radiation resistant tumors useful in predicting response to therapy and assessing risk of local-regional failure, survival and metastasis in cancer patients. Also disclosed are methods for characterizing tumors according to gene expression and kits for use in the methods of the invention.
    Type: Grant
    Filed: January 19, 2007
    Date of Patent: February 22, 2011
    Assignee: The University of Chicago
    Inventors: Ralph Weichselbaum, Bernard Roizman, Andy Minn, Nikolai Khodarev, Edwardine Labay
  • Prognosis and Therapy Predictive Markers and Methods of Use
    Publication number: 20090011439
    Abstract: Disclosed is a set of genes differentially expressed in chemotherapy and radiation resistant tumors useful in predicting response to therapy and assessing risk of local-regional failure, survival and metastasis in cancer patients. Also disclosed are methods for characterizing tumors according to gene expression and kits for use in the methods of the invention.
    Type: Application
    Filed: January 19, 2007
    Publication date: January 8, 2009
    Inventors: Ralph Weichselbaum, Bernard Roizman, Andy Minn, Nikolai Khodarev, Edwardine Labay
  • Method of Predicting and Reducing Risk of Metastasis of Breast Cancer to Lung
    Publication number: 20080213258
    Abstract: A signature for breast cancer tissue derived from a patient is established that is indicative of the virulence and risk of lung metastasis by determining the expression levels to define a sample signature, and comparing this sample signature to a reference signature. The reference signature defines a standard expression level for each gene and a significant change direction, i.e., either overexpressed or underexpressed. A sample signature that differs from the reference signature in the significant change direction for a predetermined number of the genes tested is indicative of a significant risk of lung metastasis. This determination is used to define appropriate treatment and monitoring options for the patient.
    Type: Application
    Filed: January 5, 2006
    Publication date: September 4, 2008
    Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Joan Massague, Gaorav P. Gupta, Andy Minn